Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Inflammatory Breast Cancer
Interventions: DRUG: Pembrolizumab Injection|DRUG: neoadjuvant EC-paclitaxel chemotherapy
Sponsor: Institut Paoli-Calmettes
Collaborators: MSD France|Oncodistinct